From its platform, the company has developed the promising pipeline-in-a-drug candidate asunercept. It targets the CD95 dependent signaling pathways in cancer and it plays a role in improving the immune response against cancer and viral infections. There is also a strong scientific rationale that asunercept can be developed in dermatology and ophthalmology.